LY 117018

Drug Profile

LY 117018

Latest Information Update: 30 Jul 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Antineoplastics; Pyrrolidines; Small molecules; Thiophenes
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Menopausal syndrome; Postmenopausal osteoporosis

Most Recent Events

  • 31 Mar 2000 Results of a preclinical study investigating the effect of LY 117018 on rat vaginal Candida albicans colonization has been added to the Women's Health pharmacodynamics section
  • 18 Jan 2000 Preclinical development for Postmenopausal osteoporosis (Unknown route)
  • 18 Jan 2000 Preclinical studies have been added to the Women's Health and Musculoskeletal pharmacodynamics sections (7166491 and 7166540)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top